Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Divineincon Mar 12, 2020 10:20am
69 Views
Post# 30798615

RE:PENDING GOOD NEWS

RE:PENDING GOOD NEWS
March 12, 2020 - 08:31 AM
74 Reads
Post# 30797786

PENDING GOOD NEWS


Bringing it on top again for once because of unanimity on this forum about the content. Thanks guys for your reactions.


I strongly believe we'll soon get a positive news release with announcement of partnership, buyout or licencing deal

This is my argumentation :

Without fresh money and higher Market Cap, Kalytera simply can't afford the Acquisition of Stero. Why?

These are the conditions for the acquisition of Stero:

1)Kalytera is obliged to close a Private Placement of 10 million dollar prior to the voting of acquisition and RS (1st of May). This is simply impossible. Last PP was a few months ago and Kaly hardly raised 1,5 million dollars with a lot of effort. The situation for a PP is now, at least under the current circumstances, even more difficult than it was then. They will only be able to gather 10 million if the short term outlook improves dramatically and share price increases.

Bashers will say 'Mr David Bassa will basically fund the private placement'. He will not. From his perspective, funding a PP that causes immediate massive dillution on such scale (10 million dilution equals the current Market Cap) of his 'own' stock and shares is the worst investment ever, certainly because his investment would be subject to even higher dilution caused by payment of the acquisition in shares after closing.

There's no way to raise 10 million out of a PP without announcement of good news that improves financial perspectives.  No closing of PP, no acquisition of Stero.

2)Second condition is : shareholders approval of a 100 : 1 Reverse Split. Kalytera has 80% retail investment, it's you and me, common and ordinary people invested in this stock. Nobody is going to vote pro on this subject. Kalytera needs to assemble the vast majority of votes amongst shareholder, which is only possible in case they give a good (= golden) reason to vote pro.

3)Third condition is : shareholders approval of the acquisition. Again, who among us is going to vote PRO if acquisition would only bring dilution? Again, we must be given a paid reason to vote pro.

Even though it's impossible to meet these 3 conditions under the current circumstances of low financials, Kalytera already releases the news of resignation of the board of directors.

On close of the acquisition, Mr. David Bassa, Chairman and CEO of Stero, will be appointed as Chairman and CEO of Kalytera, and Kalytera’s current board of directors will be replaced by directors to be named by Mr. Bassa. In anticipation of this, two of Kalytera’s current independent directors, Jeff Paley, M.D. and Mr. Robin Hutchison, have submitted their notices of resignation, and will be replaced by independent directors to be named by Mr. Bassa.

 

This tells me Kalytera must have strong reasons to believe the acquisition is going to be adopted for sure.

Because of all these reasons I believe Kalytera has found a golden egg that has not been released yet. The announcement of a partnership, buyout, licencing deal,... should follow soon since there's not much time left to fill in the private placement before the 1st of May. News should be out before the end of this month at the latest. 

Always do your own DD


Bullboard Posts